Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Timothy Jackson

Internal Medicine Beaver, PA Medical Doctor

NPI 1427070747 CMS profile 200771

500 Sharon Rd, Beaver, PA 15009

Open in the dashboard

General payments

$1,040

63 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$1,580,868 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Timothy Jackson of Beaver, PA is reported in the CMS Open Payments database as having received $1,040 across 63 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $1,580,868 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 70th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $109 5
2024 General $45 2
2023 General $111 6
2022 General $223 13
2021 General $95 6
2020 General $195 12
2019 General $260 19

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Timothy Jackson
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Timothy Jackson were reported at $109. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Timothy Jackson Internal Medicine median Middle half National median
2019 $260 $159 $48–$570 $163
2020 $195 $119 $33–$402 $114
2021 $95 $135 $37–$521 $132
2022 $223 $141 $42–$496 $149
2023 $111 $149 $45–$519 $160
2024 $45 $154 $47–$537 $164
2025 $109 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $315 17 payments
  2. AbbVie, Inc. $160 8 payments
  3. GlaxoSmithKline, LLC. $124 8 payments
  4. Astellas Pharma US Inc $73 5 payments
  5. Pfizer Inc. $63 4 payments
  6. Janssen Pharmaceuticals, Inc $55 4 payments
  7. AstraZeneca Pharmaceuticals LP $48 4 payments
  8. Novartis Pharmaceuticals Corporation $38 3 payments
  9. Recor Medical Inc $28 1 payment
  10. Abbott Laboratories $22 1 payment
  11. Other $113 8 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,007 61 payments
  2. Education $33 2 payments
Products named General payments · program years 2019–2025
  1. Ozempic $251 14 payments
  2. RYBELSUS $189 10 payments
  3. TRELEGY ELLIPTA $86 5 payments
  4. UBRELVY $84 4 payments
  5. MYRBETRIQ $73 5 payments
  6. XARELTO $55 4 payments
  7. INVOKANA $55 4 payments
  8. VRAYLAR $54 3 payments
  9. ELIQUIS $47 3 payments
  10. QULIPTA $42 2 payments
  11. Other $427 28 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 202 drugs

Part D claims

19,890

Median for Internal Medicine: 777

Drug cost

$1,471,721

Median for Internal Medicine: $73,373

Branded share of claims

18.8%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 422 $291,895
Ozempic Semaglutide Brand 172 $214,557
Jardiance Empagliflozin Brand 104 $105,647
Xarelto Rivaroxaban Brand 130 $103,756
Mounjaro Tirzepatide Brand 33 $42,776
Januvia Sitagliptin Phosphate Brand 32 $41,172
Myrbetriq Mirabegron Brand 73 $40,266
Basaglar Kwikpen U-100 Insulin Glargine,hum.Rec.Anlog Brand 55 $38,379
Xifaxan Rifaximin Brand 12 $35,431
Breo Ellipta Fluticasone/Vilanterol Brand 46 $27,682

The 10 drugs with the highest cost, of 202 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 33 billing codes

Paid by Medicare

$157,395

Of which drugs: $40,178

Medicare patients

311

Average age 78

Services billed

3,574

184 women, 127 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 74%
Arthritis 68%
Chronic kidney disease 32%
Diabetes 30%
Ischemic heart disease 30%
Depression 30%
Alzheimer's or dementia 25%
Atrial fibrillation 19%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, denosumab, 1 mg J0897 Office 11 1,080 $21,884
Pcv20 vaccine im 90677 Office 60 60 $17,516
Vaccine for influenza for administration into muscle, 0.5 ml dosage 90656 Office 25 25 $548

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

3 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
UBRELVY
  • AbbVie, Inc. $22
$22 — —
RYBELSUS
  • Novo Nordisk Inc $12
$12 — —
Ozempic
  • Novo Nordisk Inc $12
$12 172 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

63 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record